Skip to content
ChickenStockChickenStock
ResearchGPCR
Structure Therapeutics logo

Structure Therapeutics (GPCR) stock

NASDAQ

$18.19-2.05%(-0.38)

As of the Nov 17, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · not confirmed · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-4.44x

Net loss — not comparable

P/B

1.06x

P/S

—

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Operating income decreased from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 9, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

9 SEC filings
  • Coll Crespo BlasCHIEF MEDICAL OFFICER · Sep 21, 2026Conversion12,024 shares · $0
    Avg. price $0258,228 shares held after
  • Coll Crespo BlasCHIEF MEDICAL OFFICER · Sep 18, 2026Shares withheld for taxes10,626 shares · $124K
    Avg. price $11.67270,252 shares held after
  • Lin XichenCHIEF SCIENTIFIC OFFICER · Sep 1, 2026Option exercise17,817 shares · $6K
    Avg. price $0.34246,777 shares held after
  • Lin XichenCHIEF SCIENTIFIC OFFICER · Sep 1, 2026Conversion17,817 shares · $0
    Avg. price $0228,960 shares held after
  • Lin XichenCHIEF SCIENTIFIC OFFICER · Aug 18, 2026Option exercise11,817 shares · $4K
    Avg. price $0.34240,777 shares held after
  • Lin XichenCHIEF SCIENTIFIC OFFICER · Aug 18, 2026Conversion11,817 shares · $0
    Avg. price $0228,960 shares held after
  • Berrios John JosephChief Commercial Officer · Aug 6, 2026Grant or award140,766 shares · $0
    Avg. price $0140,766 shares held after
  • Lin XichenCHIEF SCIENTIFIC OFFICER · Aug 4, 2026Option exercise11,817 shares · $4K
    Avg. price $0.34240,777 shares held after
  • Lin XichenCHIEF SCIENTIFIC OFFICER · Aug 4, 2026Conversion11,817 shares · $0
    Avg. price $0228,960 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Structure Therapeutics (GPCR) stock information

NASDAQ

Structure Therapeutics (GPCR) is listed on NASDAQ. Its market capitalization is about $1.3B. On trailing-twelve-month earnings the P/E ratio is -4.44, and the P/B ratio is 1.06. Return on equity is -24%. These figures are computed in-house from official filings and are reference information only.

Structure Therapeutics — frequently asked questions

What is the P/E ratio of Structure Therapeutics (GPCR)?
On a trailing-twelve-month basis, GPCR trades at a P/E ratio of -4.44. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Structure Therapeutics?
GPCR has a market capitalization of about $1.3B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.